INNATE PHARMA SP.ADR/1 (F:IDDA) — Stock Price
INNATE PHARMA SP.ADR/1 (F:IDDA) is currently trading at €1.06 EUR, down 9.40% today. Over the past 52 weeks, shares have ranged between €0.93 and €2.02. This page tracks INNATE PHARMA SP.ADR/1's live share price on the F exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see market cap of INNATE PHARMA SP.ADR/1.
INNATE PHARMA SP.ADR/1 (IDDA) Stock Price Chart — Daily History & Trading Volume
The chart below tracks INNATE PHARMA SP.ADR/1's daily closing share price and trading volume on the F exchange over the past year, giving a clear view of recent price momentum and liquidity.
INNATE PHARMA SP.ADR/1 Income Statement — Revenue, Profit & Earnings by Year
INNATE PHARMA SP.ADR/1's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | €2.79 Million | €12.62 Million | €51.90 Million | €49.58 Million | €12.11 Million |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Research & Development | €43.62 Million | €51.98 Million | €56.02 Million | €51.66 Million | €47.00 Million |
| SG&A | €11.00 Million | €11.93 Million | €11.75 Million | €14.47 Million | €15.99 Million |
| Total Operating Expenses | €56.21 Million | €64.20 Million | €64.57 Million | €66.00 Million | €59.94 Million |
| Operating Income | €-53.42 Million | €-51.58 Million | €-12.67 Million | €-16.43 Million | €-47.83 Million |
| EBITDA | — | — | — | — | — |
| EBIT | — | — | — | — | — |
| Interest Expense | €440.00K | €566.00K | €640.00K | €288.00K | €312.00K |
| Income Before Tax | €-49.18 Million | €-49.47 Million | €-7.57 Million | €-57.97 Million | €-45.48 Million |
| Income Tax Expense | — | — | — | — | — |
| Net Income | €-49.18 Million | €-49.47 Million | €-7.57 Million | €-58.10 Million | €-52.81 Million |
INNATE PHARMA SP.ADR/1 Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes INNATE PHARMA SP.ADR/1's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | €62.72 Million | €111.06 Million | €175.19 Million | €199.29 Million | €267.50 Million |
| Total Current Assets | €46.71 Million | €85.74 Million | €148.01 Million | €139.83 Million | €138.26 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | €6.22 Million | €14.37 Million | €21.85 Million | €17.26 Million | €16.08 Million |
| Net Receivables | €391.00K | €650.00K | €15.23 Million | €3.08 Million | €846.00K |
| Inventory | — | — | — | — | — |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | — | — | — | — | — |
| Total Liabilities | €84.42 Million | €102.22 Million | €123.29 Million | €145.14 Million | €160.06 Million |
| Total Current Liabilities | €36.65 Million | €32.98 Million | €39.64 Million | €41.34 Million | €79.89 Million |
| Long-term Debt | €13.67 Million | €22.18 Million | €30.61 Million | €38.93 Million | €11.49 Million |
| Net Debt | — | — | — | — | — |
| Total Stockholder Equity | €-21.70 Million | €8.83 Million | €51.90 Million | €54.15 Million | €107.44 Million |
| Retained Earnings | €-435.54 Million | €-386.36 Million | €-336.89 Million | €-330.32 Million | €-272.21 Million |
INNATE PHARMA SP.ADR/1 Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how INNATE PHARMA SP.ADR/1 generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | €-32.56 Million | €-6.90 Million | €-32.56 Million | €-19.16 Million | €-58.46 Million |
| Capital Expenditures | €2.35 Million | €391.00K | €2.35 Million | €1.12 Million | €1.33 Million |
| Free Cash Flow | €-34.91 Million | €-7.29 Million | €-34.91 Million | €-20.28 Million | €-59.79 Million |
| Investing Cash Flow | — | — | — | — | — |
| Financing Cash Flow | €-1.97 Million | €-6.01 Million | €-1.97 Million | €-1.83 Million | €26.82 Million |
| Dividends Paid | — | — | €0.00 | €0.00 | €0.00 |
| Stock-Based Compensation | €4.26 Million | €3.94 Million | €4.26 Million | €4.25 Million | €2.62 Million |
| Depreciation | €5.09 Million | €1.99 Million | €5.09 Million | €45.41 Million | €4.60 Million |
| Change in Cash | €-13.62 Million | €-4.21 Million | €-13.62 Million | €-19.53 Million | €-33.04 Million |
INNATE PHARMA SP.ADR/1 Earnings History — EPS Actual vs. Analyst Estimates
Track INNATE PHARMA SP.ADR/1's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| May 13, 2026 | — | -0.16 | — |
| Mar 26, 2026 | — | -0.14 | — |
| Nov 13, 2025 | — | -0.14 | — |
| Sep 17, 2025 | — | — | — |
| May 12, 2025 | — | — | — |